MV Chandrakanth (@chandrakanthmv) 's Twitter Profile
MV Chandrakanth

@chandrakanthmv

I am a medical oncologist working in Kolkata .I am from Bangalore ,now residing in kolkata

ID: 1378012579419721728

calendar_today02-04-2021 15:53:12

23 Tweet

116 Followers

133 Following

MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

PTEN loss isn’t just another mutation — it removes the brake on the PI3K–AKT–mTOR pathway 🚦 When AKT is addicted, target the right node. IHC or NGS? Baseline or rebiopsy? Mechanism should guide medicine. #MVOnco #Oncology #PrecisionMedicine

PTEN loss isn’t just another mutation — it removes the brake on the PI3K–AKT–mTOR pathway 🚦
When AKT is addicted, target the right node.
IHC or NGS? Baseline or rebiopsy?
Mechanism should guide medicine.
#MVOnco #Oncology #PrecisionMedicine
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Blocking the same pathway at different levels — output, input, or the engine itself. Everolimus → Broad suppression Alpelisib → PIK3CA-specific Capivasertib → AKT-node precision Match the mutation. Target the dependency. #MVOnco #BreastCancer #PrecisionOncology #MedOnc

Blocking the same pathway at different levels — output, input, or the engine itself.
Everolimus → Broad suppression
Alpelisib → PIK3CA-specific
Capivasertib → AKT-node precision
Match the mutation. Target the dependency.
#MVOnco #BreastCancer #PrecisionOncology #MedOnc
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

In PTEN-deficient mHSPC, adding capivasertib to abiraterone improves rPFS by +7.5 months (HR 0.81) and delays hormonal escape (TTCR HR 0.77). Target the biology — not just AR. #MVOnco #ProstateCancer #mHSPC #PrecisionOncology

In PTEN-deficient mHSPC, adding capivasertib to abiraterone improves rPFS by +7.5 months (HR 0.81) and delays hormonal escape (TTCR HR 0.77).
Target the biology — not just AR.
#MVOnco #ProstateCancer #mHSPC #PrecisionOncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

• CAPItello-281 PRO data (ASCO GU 2026) • rPFS improved • No clinically meaningful HRQoL decline • Functional wellbeing preserved • Early AKT-related AEs manageable Precision intensification without compromising daily life. #MVOnco #ASCOGU #mHSPC #ProstateCancer

• CAPItello-281 PRO data (ASCO GU 2026)
• rPFS improved
• No clinically meaningful HRQoL decline
• Functional wellbeing preserved
• Early AKT-related AEs manageable
Precision intensification without compromising daily life.
#MVOnco #ASCOGU #mHSPC #ProstateCancer
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

PEACE-3 (ASCO GU 2026) delivers final OS. Enzalutamide + Radium-223: 38.2 vs 32.6 mo (HR 0.75). 25% ↓ risk of death in bone-dominant mCRPC. Systemic + bone-targeted synergy confirmed. #MVOnco #ASCOGU #mCRPC #ProstateCancer

PEACE-3 (ASCO GU 2026) delivers final OS.
Enzalutamide + Radium-223: 38.2 vs 32.6 mo (HR 0.75).
25% ↓ risk of death in bone-dominant mCRPC.
Systemic + bone-targeted synergy confirmed.
#MVOnco #ASCOGU #mCRPC #ProstateCancer
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Radium-223 or Lu-PSMA in mCRPC? Bone-dominant disease → Radium-223 (+ Enza now OS-validated in PEACE-3). PSMA+ systemic spread → Lu-PSMA. Alpha vs beta. Bone-targeted vs whole-body. Choose the biology. #MVOnco #ASCOGU #mCRPC #ProstateCancer #Theranostics

Radium-223 or Lu-PSMA in mCRPC?
Bone-dominant disease → Radium-223 (+ Enza now OS-validated in PEACE-3).
PSMA+ systemic spread → Lu-PSMA.
Alpha vs beta. Bone-targeted vs whole-body.
Choose the biology.
#MVOnco #ASCOGU #mCRPC #ProstateCancer #Theranostics
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

PD-L1 <1% in advanced NSCLC? Real-world data (Lung Cancer 2026) show NIVO+IPI+chemo delivers 47.4 mo median OS vs 16.6 mo with PEMBRO+chemo (HR 0.50). No difference if PD-L1 ≥1%. Is dual IO the edge in PD-L1 negative disease? #MVOnco #NSCLC

PD-L1 &lt;1% in advanced NSCLC?
Real-world data (Lung Cancer 2026) show NIVO+IPI+chemo delivers 47.4 mo median OS vs 16.6 mo with PEMBRO+chemo (HR 0.50).
No difference if PD-L1 ≥1%.
Is dual IO the edge in PD-L1 negative disease?
#MVOnco #NSCLC
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

In muscle-invasive bladder cancer: Urine tumor DNA fell from 85% → 55% after neoadjuvant therapy. If utDNA cleared → much lower recurrence risk (HR 0.24). utDNA− before surgery → 72% pCR. Blood + urine together = better prediction. #MVOnco #BladderCancer #MIBC #ctDNA

In muscle-invasive bladder cancer:
Urine tumor DNA fell from 85% → 55% after neoadjuvant therapy.
If utDNA cleared → much lower recurrence risk (HR 0.24).
utDNA− before surgery → 72% pCR.
Blood + urine together = better prediction.
#MVOnco #BladderCancer #MIBC #ctDNA
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

KIM-1 in RCC — why should we care? 🧬 It’s a protein released by kidney cancer cells 📈 It may rise before scans show relapse 🧠 It reflects tumor biology, not just tumor size In RCC, biology may speak before imaging. #MVOnco #RCC #KidneyCancer #GUOncology #Oncology

KIM-1 in RCC — why should we care?
🧬 It’s a protein released by kidney cancer cells
📈 It may rise before scans show relapse
🧠 It reflects tumor biology, not just tumor size
In RCC, biology may speak before imaging.
#MVOnco #RCC #KidneyCancer #GUOncology #Oncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

CYTOSHRINK trial looked at adding focused radiation (SBRT) to the kidney tumor along with Ipilimumab + Nivolumab in metastatic kidney cancer. 👉 It was safe. 👉 But it did NOT improve survival or delay progression. #MVOnco #KidneyCancer #RCC #Immunotherapy #ASCOGU #Oncology

CYTOSHRINK trial looked at adding focused radiation (SBRT) to the kidney tumor along with Ipilimumab + Nivolumab in metastatic kidney cancer.
👉 It was safe.
👉 But it did NOT improve survival or delay progression.
#MVOnco #KidneyCancer #RCC #Immunotherapy #ASCOGU #Oncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Stage I seminoma after orchiectomy 👇 ✔ Reliable follow-up → Active surveillance (preferred) ~15% relapse, salvage effective, survival ≈99% ❌ Not reliable → Carboplatin or RT Choice = follow-up reliability. #MVOnco #TesticularCancer #GUOncology

Stage I seminoma after orchiectomy 👇
✔ Reliable follow-up → Active surveillance (preferred)
~15% relapse, salvage effective, survival ≈99%
❌ Not reliable → Carboplatin or RT
Choice = follow-up reliability.
#MVOnco #TesticularCancer  #GUOncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Stage I NSGCT after surgery 👇 First, check 3 risk factors: • LVI • EC • T3/T4 If none → relapse ~10% If T3/T4 only → ~20% If LVI or EC → relapse ~50% Good news: cure rates ≈99% with all options. #MVOnco #TesticularCancer #NSGCT

Stage I NSGCT after surgery 👇
First, check 3 risk factors:
• LVI
• EC
• T3/T4
If none → relapse ~10%
If T3/T4 only → ~20%
If LVI or EC → relapse ~50%
Good news: cure rates ≈99% with all options.
#MVOnco #TesticularCancer #NSGCT
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

TRISST trial (JCO 2022) 👇 In Stage I seminoma on surveillance: • MRI is as good as CT • 3 scans can be as safe as 7 scans • No difference in survival Less radiation. Same cure rates. Smarter, safer follow-up for young men. #MVOnco #Seminoma #TesticularCancer #GUOncology

TRISST trial (JCO 2022) 👇
In Stage I seminoma on surveillance:
• MRI is as good as CT
• 3 scans can be as safe as 7 scans
• No difference in survival
Less radiation. Same cure rates.
Smarter, safer follow-up for young men.
#MVOnco #Seminoma #TesticularCancer #GUOncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

🧬 What if we had a blood test that detects active germ cell tumor cells — even when AFP & β-hCG are normal? miR-371 is changing how we diagnose and monitor testicular cancer. But remember: it doesn’t detect teratoma. #MVOnco #TesticularCancer #Oncology

🧬 What if we had a blood test that detects active germ cell tumor cells — even when AFP &amp; β-hCG are normal?
miR-371 is changing how we diagnose and monitor testicular cancer.
But remember: it doesn’t detect teratoma.
#MVOnco #TesticularCancer #Oncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Stage 1 testicular cancer: CT scan normal after surgery… but 20–30% still relapse. CLIMATE study shows a blood test (miR-371) can predict relapse risk (HR ~10). Early MRD signal — promising, but needs more validation. #MVOnco #TesticularCancer #Oncology

Stage 1 testicular cancer:
CT scan normal after surgery… but 20–30% still relapse.
CLIMATE study shows a blood test (miR-371) can predict relapse risk (HR ~10).
Early MRD signal — promising, but needs more validation.
#MVOnco #TesticularCancer #Oncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Is MRD redefining adjuvant therapy? In Stage I TGCT, miR-371 predicts relapse (HR ~10). In Stage II colon cancer, ctDNA helps decide who can safely avoid chemo. From predicting risk to guiding treatment — the MRD era is here? #MVOnco #MRD #Oncology

Is MRD redefining adjuvant therapy?
In Stage I TGCT, miR-371 predicts relapse (HR ~10).
In Stage II colon cancer, ctDNA helps decide who can safely avoid chemo.
From predicting risk to guiding treatment — the MRD era is here?
#MVOnco #MRD #Oncology
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Relapsed germ cell tumor after multiple lines of chemo — what next? Phase II data shows cabozantinib achieved disease control in 43% of heavily pretreated patients, with strong tumor marker reduction. Not curative, but a meaningful option. #MVOnco #GCT

Relapsed germ cell tumor after multiple lines of chemo — what next?
Phase II data shows cabozantinib achieved disease control in 43% of heavily pretreated patients, with strong tumor marker reduction.
Not curative, but a meaningful option.
#MVOnco #GCT
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Residual HER2+ disease after neoadjuvant therapy isn’t equal. Bulky tumor + node-positive = higher risk → consider T-DXd. Minimal residual focus = lower risk → T-DM1 may suffice. Escalate when risk persists. Individualize when it doesn’t. #MVOnco #BreastCancer

Residual HER2+ disease after neoadjuvant therapy isn’t equal.
Bulky tumor + node-positive = higher risk → consider T-DXd.
Minimal residual focus = lower risk → T-DM1 may suffice.
Escalate when risk persists.
Individualize when it doesn’t.
#MVOnco #BreastCancer
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Weather changes daily. Climate changes slowly. In oncology, DYNAMIC reshaped colon cancer using ctDNA. Now CLIMATE with miR-371 in testis is guiding smarter decisions. Is the treatment climate becoming dynamic? 🌍🧬 #MRD #Oncology #ASCOGU26 #MVOnco

Weather changes daily.
Climate changes slowly.

In oncology, DYNAMIC reshaped colon cancer using ctDNA.
Now CLIMATE with miR-371 in testis is guiding smarter decisions.
Is the treatment climate becoming dynamic? 🌍🧬

#MRD #Oncology #ASCOGU26 #MVOnco
MV Chandrakanth (@chandrakanthmv) 's Twitter Profile Photo

Cytoreductive nephrectomy in metastatic RCC has evolved. Not routine anymore. Start immunotherapy first. Restage. Operate only on responders. It’s no longer dogma — it’s biology-driven strategy. #RCC #KidneyCancer #Immunotherapy #MVOnco

Cytoreductive nephrectomy in metastatic RCC has evolved.
Not routine anymore.
Start immunotherapy first.
Restage.
Operate only on responders.
It’s no longer dogma — it’s biology-driven strategy.
#RCC #KidneyCancer #Immunotherapy #MVOnco